Takeda Pharmaceutical (TKPHF) Total Debt (2018 - 2026)

Takeda Pharmaceutical's Total Debt history runs 9 years deep, the most recent figure standing at $31.5 billion for Q1 2026.

• In Q1 2026, Total Debt rose 6.41% year-over-year to $31.5 billion; the TTM figure through Mar 2026 stood at $31.5 billion (up 6.41% YoY), while the FY2026 annual figure was $32.8 billion, up 10.69% from the prior year.
• Total Debt was $31.5 billion for Q1 2026 at Takeda Pharmaceutical, roughly flat from $31.4 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $37.3 billion in Q2 2022 to a low of $5.6 billion in Q1 2024.
• Historically, Total Debt has averaged $30.1 billion across 5 years, with a median of $33.1 billion in 2023.
• The sharpest annual moves came in 2023 and 2024: Total Debt soared 478.96% in 2023, then tumbled 83.07% in 2024.
• A 5-year view of Total Debt shows it stood at $31.3 billion in 2022, then increased by 4.61% to $32.7 billion in 2023, then advanced by 6.47% to $34.8 billion in 2024, then decreased by 9.74% to $31.4 billion in 2025, then rose by 0.2% to $31.5 billion in 2026.
• The last three Total Debt figures came in at $31.5 billion (Q1 2026), $31.4 billion (Q4 2025), and $33.2 billion (Q3 2025), per Business Quant data.